These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 30429093)

  • 21. Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma.
    Carpagnano GE; Resta E; Povero M; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Barbaro MPF
    Sci Rep; 2021 Mar; 11(1):5453. PubMed ID: 33750842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and economic burden of severe asthma among US patients treated with biologic therapies.
    Reibman J; Tan L; Ambrose C; Chung Y; Desai P; Llanos JP; Moynihan M; Tkacz J
    Ann Allergy Asthma Immunol; 2021 Sep; 127(3):318-325.e2. PubMed ID: 33775904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Severe uncontrolled asthma in patients over 75 years old: Treatment with omalizumab].
    Romand P; Kelkel E; Saint-Raymond C; Glas N; Caillaud D; Devouassoux G
    Rev Mal Respir; 2016 May; 33(5):397-400. PubMed ID: 26346416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study.
    Pérez de Llano LA; Cosío BG; Domingo C; Urrutia I; Bobolea I; Valero A; Entrenas Costa LM; Quirce S; Barranco P; Marina Malanda N; Andrés LP; Alvarez-Gutiérrez FJ
    J Allergy Clin Immunol Pract; 2019; 7(7):2277-2283.e2. PubMed ID: 30677539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study.
    Pelaia C; Calabrese C; Barbuto S; Busceti MT; Preianò M; Gallelli L; Savino R; Vatrella A; Pelaia G
    Pulm Pharmacol Ther; 2019 Feb; 54():25-30. PubMed ID: 30414440
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Omalizumab versus Mepolizumab as add-on therapy in asthma patients not well controlled on at least an inhaled corticosteroid: A network meta-analysis.
    Nachef Z; Krishnan A; Mashtare T; Zhuang T; Mador MJ
    J Asthma; 2018 Jan; 55(1):89-100. PubMed ID: 28459601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose?
    Giovannini M; Mori F; Barni S; de Martino M; Novembre E
    Ital J Pediatr; 2019 Nov; 45(1):151. PubMed ID: 31779657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does omalizumab make a difference to the real-life treatment of asthma exacerbations?: Results from a large cohort of patients with severe uncontrolled asthma.
    Grimaldi-Bensouda L; Zureik M; Aubier M; Humbert M; Levy J; Benichou J; Molimard M; Abenhaim L;
    Chest; 2013 Feb; 143(2):398-405. PubMed ID: 23505637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monoclonal antibodies for severe asthma: Pharmacokinetic profiles.
    Matera MG; Calzetta L; Rogliani P; Cazzola M
    Respir Med; 2019 Jul; 153():3-13. PubMed ID: 31136930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the Efficacy of Omalizumab and Mepolizumab in Non-Steroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease.
    Cihanbeylerden M; Tuncay G; Kayıkçı H; Damadoglu E; Karakaya G; Kalyoncu AF
    Int Arch Allergy Immunol; 2024; 185(10):947-952. PubMed ID: 38865992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-Life Effectiveness of Benralizumab, Mepolizumab and Omalizumab in Severe Allergic Asthma Associated with Nasal Polyps.
    Tiotiu A; Mendez-Brea P; Ioan I; Romero-Fernandez R; Oster JP; Hoang TC; Roux P; Ochoa-Gutierrez DC; Bonniaud P; de Blay F; Gonzalez-Barcala FJ
    Clin Rev Allergy Immunol; 2023 Apr; 64(2):179-192. PubMed ID: 35420388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of omalizumab in severe asthmatics across ages: A real life Italian experience.
    Sposato B; Scalese M; Latorre M; Scichilone N; Matucci A; Milanese M; Masieri S; Rolla G; Steinhilber G; Rosati Y; Vultaggio A; Folletti I; Baglioni S; Bargagli E; Di Tomassi M; Pio R; Pio A; Maccari U; Maggiorelli C; Migliorini MG; Vignale L; Pulerà N; Carpagnano GE; Foschino Barbaro MP; Perrella A; Paggiaro PL
    Respir Med; 2016 Oct; 119():141-149. PubMed ID: 27692136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical and economic analysis of Reslizumab use in the treatment of patients with severe allergic eosinophilic asthma].
    Kolbin AS; Avdeev SN; Zhuravleva MV; Gomon YM; Balykina YE; Matveyev NV; Proskurin MA; Fedosenko SV
    Ter Arkh; 2019 Dec; 91(12):47-56. PubMed ID: 32598589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response to omalizumab in patients with severe allergic asthma: A real-life study.
    Zierau L; Walsted ES; Thomsen SF; Backer V
    Respir Med; 2017 Oct; 131():109-113. PubMed ID: 28947015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-life long-term omalizumab therapy in children with severe allergic asthma.
    Deschildre A; Marguet C; Langlois C; Pin I; Rittié JL; Derelle J; Abou Taam R; Fayon M; Brouard J; Dubus JC; Siret D; Weiss L; Pouessel G; Beghin L; Just J
    Eur Respir J; 2015 Sep; 46(3):856-9. PubMed ID: 26022964
    [No Abstract]   [Full Text] [Related]  

  • 36. Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab.
    Pérez de Llano LA; Dacal Rivas D; Cosío BG
    Allergy; 2020 Apr; 75(4):940-942. PubMed ID: 31483864
    [No Abstract]   [Full Text] [Related]  

  • 37. Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one center's early clinical experience.
    Weir E; Paton J
    J Asthma; 2020 May; 57(5):521-524. PubMed ID: 30795693
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma.
    Busse WW; Humbert M; Haselkorn T; Ortiz B; Trzaskoma BL; Stephenson P; Garcia Conde L; Kianifard F; Holgate ST
    Ann Allergy Asthma Immunol; 2020 Feb; 124(2):190-196. PubMed ID: 31760132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Analysis of asthma control and quality of life in severe allergic asthmatics under treatment with anti-IgE, omalizumab].
    Pacheco-Galván A; Hinojosa-Macías M; Hurtado-Barbudo B; González-Cervera J; Sueiro-Bendito A
    Med Clin (Barc); 2009 Oct; 133(12):460-3. PubMed ID: 19775710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Severe asthma with eosinophilic gastroenteritis effectively managed by mepolizumab and omalizumab.
    Han D; Lee JK
    Ann Allergy Asthma Immunol; 2018 Dec; 121(6):742-743. PubMed ID: 30056148
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.